Better understanding the development/maintenance of GLP‐1 neurons, combinatorial therapy involving GLP‐1 designer agonists, as well as the acute versus chronic effects of GLP‐1 on the brain will undoubtedly be growing areas of study to better understand the therapeutic benefits of this system in metabolic disease. The gene discussed is GCG; the disease is Other metabolic disease.